Royalty Pharma agrees to acquire royalty interest in Trelegy Ellipta from Theravance and Innoviva

Client(s) RP Management LLC

Jones Day advised Royalty Pharma in the acquisition of a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. and Innoviva, Inc. for an upfront payment of $1.31 billion and additional payments of up to $300 million contingent on achieving certain sales milestones.